Robert Hodgson

18PUBLICATIONS
56CO-AUTHORS
Predictive and prognostic markersMajor global burdens of diseaseCancer diagnosisEpidemiological modellingMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Feb 24, 2026
Schrodinger's Pricing: Conceptual and Practical Challenges of Conditional PAS in the NICE Technology Appraisal of Lorlatinib for Untreated ALK-Positive Advanced Non-small-cell Lung Cancer (Review of TA1103): An External Assessment Group Perspective.

Robert Hodgson, Diarmuid Coughlan

|Feb 16, 2026
Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis.

Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt

|Feb 09, 2026
Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessment.

Matthew Walton, Alexis Llewellyn, Eleonora Uphoff

|Nov 18, 2025
The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS.

Matthew Walton, Nyanar Jasmine Deng, Mark Corbett

|Nov 03, 2025
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

Matthew Walton, Nyanar J Deng, Mark Corbett

|Aug 22, 2025
Enzyme replacement therapy for the treatment of late onset Pompe disease: A systematic review and network meta-analysis.

Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt

Pageof 3

Frequent Collaborators

9 joint publications

Helen Fulbright

8 joint publications

Mark Simmonds

8 joint publications

Matthew Walton

7 joint publications

Sofia Dias